BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 12500185)

  • 1. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
    Chen RY; Edwards R; Shaw T; Colledge D; Delaney WE; Isom H; Bowden S; Desmond P; Locarnini SA
    Hepatology; 2003 Jan; 37(1):27-35. PubMed ID: 12500185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.
    Tacke F; Gehrke C; Luedde T; Heim A; Manns MP; Trautwein C
    J Virol; 2004 Aug; 78(16):8524-35. PubMed ID: 15280461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
    Zhu Y; Curtis M; Borroto-Esoda K
    Antivir Chem Chemother; 2011 Aug; 22(1):13-22. PubMed ID: 21860069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains.
    Herbers U; Amini-Bavil-Olyaee S; Mueller A; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2013 Feb; 20(2):141-8. PubMed ID: 23301549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to adefovir depends on mutation patterns in precore region, basal core promoter and reverse transcriptase, and on-treatment responses in Lamivudine-resistant chronic hepatitis B patients.
    Song BC; Cui XJ; Shin JW; Park NH; Cho YK; Song HJ; Hyun S; Jeong SU; Choi EK; Kim HU
    Intervirology; 2010; 53(4):203-10. PubMed ID: 20332649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Sheldon J; Luedde T; Trautwein C; Tacke F
    Hepatology; 2009 Apr; 49(4):1158-65. PubMed ID: 19263474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.
    Jacquard AC; Brunelle MN; Pichoud C; Durantel D; Carrouée-Durantel S; Trepo C; Zoulim F
    Antimicrob Agents Chemother; 2006 Mar; 50(3):955-61. PubMed ID: 16495257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
    Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
    J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
    Cha CK; Kwon HC; Cheong JY; Cho SW; Hong SP; Kim SO; Yoo WD
    J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
    J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
    Amini-Bavil-Olyaee S; Herbers U; Mohebbi SR; Sabahi F; Zali MR; Luedde T; Trautwein C; Tacke F
    J Hepatol; 2009 Oct; 51(4):647-54. PubMed ID: 19586679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
    Inoue J; Ueno Y; Wakui Y; Niitsuma H; Fukushima K; Yamagiwa Y; Shiina M; Kondo Y; Kakazu E; Tamai K; Obara N; Iwasaki T; Shimosegawa T
    J Viral Hepat; 2011 Mar; 18(3):206-15. PubMed ID: 20367795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
    Suzuki F; Kumada H; Nakamura H
    J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
    Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
    Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
    Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy.
    Chang UI; Lee YC; Wie SH; Jang JW; Bae SH; Choi JY; Yang JM; Yoon SK; Sun HS
    J Med Virol; 2007 Jul; 79(7):902-10. PubMed ID: 17516533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of patients with chronic hepatitis B with adefovir dipivoxil.
    Tong MJ; Tu SS
    Semin Liver Dis; 2004; 24 Suppl 1():37-44. PubMed ID: 15192800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients].
    Cho JH; Cheong JY; Kang JK; Park JS; Lee MH; Lim NK; Hong SP; Kim SO; Yoo WD; Cho SW
    Korean J Hepatol; 2008 Mar; 14(1):58-66. PubMed ID: 18367858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.